Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

BACKGROUND: Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Cortellini, Alessio, Cannita, Katia, Parisi, Alessandro, Lanfiuti Baldi, Paola, Venditti, Olga, D’Orazio, Carla, Dal Mas, Antonella, Calvisi, Giuseppe, Giordano, Aldo V, Vicentini, Vincenzo, Vicentini, Roberto, Felicioni, Lara, Marchetti, Antonio, Buttitta, Fiamma, Russo, Antonio, Ficorella, Corrado
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2019
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6438145/
https://ncbi.nlm.nih.gov/pubmed/30988620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S194745
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller